Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (DMTK) pioneers noninvasive molecular diagnostics for skin cancer detection, transforming dermatology through adhesive patch sampling and gene expression analysis. This page aggregates official announcements and verified developments about the company’s clinical advancements, financial updates, and operational milestones.
Investors and healthcare professionals will find timely updates on earnings reports, partnership agreements, and technological innovations. All content is curated to provide actionable insights into DermTech’s progress in reducing unnecessary biopsies through its CLIA-certified laboratory solutions.
Key updates include regulatory filings, research collaborations, and diagnostic technology enhancements. Each news item is vetted for relevance to the company’s mission of advancing precision dermatology while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to DermTech’s evolving role in molecular diagnostics. Regularly updated with press releases and objective analyses, it serves as your primary resource for tracking this innovator’s impact on noninvasive healthcare solutions.
DermTech, Inc. (NASDAQ: DMTK) has announced its upcoming presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 4:35 p.m. ET. The live webcast will be accessible through the Investor Relations section of DermTech's website, with an archived version available for 90 days post-event. DermTech is pioneering precision dermatology using a non-invasive skin genomics platform aimed at early skin cancer detection and treatment customization. For further information, visit DermTech.com.
DermTech (NASDAQ: DMTK) will present its DermTech Melanoma Test at the 2021 Florida Association of Health Plans annual conference from November 14-16. The Chief Medical Officer, Dr. Loren Clarke, will discuss the benefits of early melanoma detection through genomic analysis. Notably, Florida sees about 10% of U.S. melanoma cases annually. DermTech aims to enhance patient care and economic outcomes with its non-invasive testing approach, having recently joined FAHP as an associate member in August 2021.
DermTech (NASDAQ: DMTK) announced its participation in the Lake Street 2021 BIG5 Conference on September 14, 2021. As a leader in precision dermatology, DermTech utilizes a non-invasive skin genomics platform aimed at early cancer detection and customized treatments for inflammatory diseases. Their mission is to democratize dermatology care and enhance patient outcomes through innovative genomic analysis. For more information, visit www.DermTech.com.
DermTech (NASDAQ: DMTK) reported impressive financial results for Q2 2021, showcasing a 269% year-over-year increase in total revenue to $3.1 million, driven by a 267% rise in billable sample volume. Assay revenue surged 349% to $2.9 million. The company achieved a positive assay gross margin of 11%, compared to negative margins in 2020. Cash and equivalents stood at $268.3 million. DermTech also launched PLAplus for improved melanoma detection and provided updated revenue guidance of $11.5 million to $13.5 million for the full year, indicating strong growth prospects.
DermTech, Inc. (NASDAQ: DMTK) will release its Q2 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET that same day, where the company will discuss financial outcomes and recent highlights. Interested participants can join via phone or through a live webinar accessible on DermTech's investor website. DermTech is a leader in precision dermatology using non-invasive skin genomics, focusing on early skin cancer detection and customized drug treatments.
DermTech (NASDAQ: DMTK) announced plans to expand its operations in San Diego by leasing a 96,000 square-foot facility from Kilroy Realty. This new headquarters will house the DermTech Gene Lab, enabling enhanced capacity for processing the DermTech Melanoma Test, crucial for early melanoma detection. The building transformation includes converting 30,000 square feet to laboratory space, with an expected multi-phase opening starting soon. The lease spans 126 months with options for extensions. This expansion reflects DermTech's strategy to capture market opportunities in the growing biotech field.
DermTech (NASDAQ: DMTK) has appointed Monica Tellado, former Senior VP of Finance at Gilead Sciences, to its Board of Directors. This move is seen as beneficial for DermTech's growth strategy, as Tellado brings extensive experience in commercializing products and operational excellence. With 18 years at Gilead, she led market entry strategies and managed significant business units, including a $2 billion Liver Disease division. Tellado aims to advance DermTech’s mission of revolutionizing skin health through genomics, marking a pivotal point in the company’s growth trajectory.
DermTech (NASDAQ: DMTK) has announced a collaboration with researchers from the University of Barcelona to explore targeted therapies for inflammatory skin diseases like atopic dermatitis and psoriasis. This study utilizes DermTech’s Smart StickerTM platform to examine inflammatory pathways. With significant prevalence in both children and adults, these conditions incur substantial social and economic costs. The partnership aims to enhance the understanding of these diseases and the effectiveness of personalized treatments, reflecting DermTech's commitment to precision dermatology.
DermTech (NASDAQ: DMTK) announced key leadership appointments, including Loren Clarke, M.D. as Chief Medical Officer, Ray Bassi as Vice President of Sales, and Patrick Johnson as Vice President of IT and Digital Systems. Dr. Clarke brings extensive experience in dermatopathology, and Bassi has over 25 years in sales, previously with Dermira. Johnson has a strong background in IT leadership. This strategic move aims to enhance DermTech's mission in precision dermatology, focusing on non-invasive genomic testing, improving patient care, and supporting commercial growth initiatives.
